CN102133346A - Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae - Google Patents
Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae Download PDFInfo
- Publication number
- CN102133346A CN102133346A CN2011100693891A CN201110069389A CN102133346A CN 102133346 A CN102133346 A CN 102133346A CN 2011100693891 A CN2011100693891 A CN 2011100693891A CN 201110069389 A CN201110069389 A CN 201110069389A CN 102133346 A CN102133346 A CN 102133346A
- Authority
- CN
- China
- Prior art keywords
- layer
- rhizoma gastrodiae
- coating
- weightening finish
- rhizoma chuanxiong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae, which is a multi-layer coating preparation. The medicinal preparation has a basic structure formed by a medicine containing core, a swelling layer and a retardant layer which are arranged from inside to the outside. The pulse releasing oral medicinal preparation has the beneficial effects that the releasing has the characteristics that a certain dosage of medicine is released rapidly after a section of lagging time, so that the delaying and pulsing medicine releasing effect is achieved, the dose can be impacted so as to partly overcome the first pass effect of medicine, the bioavailability and the curative effect of medicine are improved, the dosing times are reduced, and the compliance of a patient is improved.
Description
Technical field
The present invention relates to a kind of oral drug preparation, relate in particular to a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae.
Background technology
Migraine and migraine apoplexy are a kind of constitutional cerebral dysfunction diseases of common pilosity, and it is fallen ill usually at 4-7 point in morning, has the division of day and night rhythmicity.Rhizoma Chuanxiong and Rhizoma Gastrodiae are the conventional Chinese medicines of clinical treatment migraine and migraine apoplexy, the dosage form that contains the compound Chinese medicinal preparation of Rhizoma Chuanxiong and Rhizoma Gastrodiae at present relates to tablet, pill, capsule, granule, injection, slow releasing tablet etc., because the main effective ingredient in Rhizoma Chuanxiong and the Rhizoma Gastrodiae absorbs, accretion rate is all very fast, and these dosage forms are not considered the division of day and night rhythmicity of migraine morbidity, so the ordinary preparation and the slow releasing tablet of the compound Chinese medicinal preparation of Rhizoma Chuanxiong and Rhizoma Gastrodiae, exist bioavailability low, curative effect is relatively poor.
Summary of the invention
The object of the present invention is to provide a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae, characteristics of incidence according to effect component physicochemical property, absorption characteristic, effect characteristics and treatment disease in the side designs, the oral back of said preparation medicine does not discharge immediately, but lag behind when certain, medicine discharges from preparation rapidly, can partly overcome the medicine first pass effect with aggressive dosage, effectively improve the treatment of bioavailability of medicament and medicine, imitate and reduce administration number of times, increase compliance of patients.
The present invention is achieved like this, and it is characterized in that said preparation is the multiple coatings preparation, and basic structure is respectively pastille core, swell layer, block layer composition from inside to outside.
Described pastille core is granule, micropill, micro chip and the tablet formulation form that contains medicine; Swell layer is the coatings of imbibition type adjuvant; Block layer contains coating adjuvants such as acrylic resin polymer or ethyl cellulose;
When a is micropill
Contain pill core and comprise Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, disintegrating agent, filler, by weight, its ratio is 3～12:12～48:1～10:69～60; Swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, and its weight ratio can be between 10:1～1:10, and the weightening finish of the coating of pastille core is 50%～80% relatively; Block layer contains hydrophobic coatings adjuvants such as acrylic resin polymer or ethyl cellulose, is 65%～100% with respect to the weightening finish of the coating of pastille core;
When b is microplate
The pastille core comprises Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, filler, disintegrating agent, its weight ratio is 4～11:29～39:37～49:7～21, wherein swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, swell layer and the weightening finish of block layer coating are than being controlled between 1:2～4:1, the swell layer weightening finish is for containing 3%～8% of the tablet heart, and the weightening finish of block layer swell layer is for containing 2%～6% of the tablet heart;
When c is tablet
The pastille core comprises Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, filler, disintegrating agent, its weight ratio is 4～11:29～39:29～42:19～38, wherein swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, swell layer and the weightening finish of block layer coating are than caning be controlled between 5:3～7:2, the swell layer weightening finish is for containing 3%～7% of the tablet heart, and the weightening finish of block layer swell layer is for containing 2%～5% of the tablet heart;
When d is granule
Contain pill core and comprise Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, disintegrating agent, filler, by weight, its ratio is 16～40:4～10:1～10:68～38; Swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, and its weight ratio can be between 10:1～1:10, and the weightening finish of the coating of pastille core is 50%～80% relatively; Block layer contains hydrophobic coatings adjuvants such as acrylic resin polymer or ethyl cellulose, is 65%～100% with respect to the weightening finish of the coating of pastille core.
Described disintegrating agent is selected from crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, the low mixture of getting a kind of in low hydroxypropyl cellulose, the microcrystalline Cellulose or some kinds.
Described swell layer coating material is hydroxypropyl methylcellulose, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, the low mixture of getting a kind of in low hydroxypropyl cellulose, the crospolyvinylpyrrolidone or some kinds.
Described block layer coating material is the mixture of a kind of of cellulose acetate-phthalate, Hydroxypropyl Methylcellulose Phathalate, phthalic acid polyvinyl alcohol ester, styrene maleic acid copolymerization, acrylic resin, Opadry enteric material, alginate jelly, Lac enteric-coating material, cellulose acetate, ethyl cellulose, polyacrylic resin class sustained release coating material or some kinds.
The adjuvant of described solubilising or raising medicine dispersion is the hydrophilic material that cyclodextrin, polyethylene glycols, polyvidone class, organic acid, saccharide and alcohols or other can be used for the solid dispersion preparation.
Described filler is for selecting the pharmacy acceptable auxiliary for use.
Technique effect of the present invention is: its release characteristic is the time hysteresis through after a while, can discharge the medicine of doses rapidly, the release effect that so-called delay and pulse are promptly arranged, can partly overcome the medicine first pass effect with aggressive dosage, effectively improve the treatment of bioavailability of medicament and medicine, imitate and reduce administration number of times, increase compliance of patients.
Description of drawings
Fig. 1 is the release curve of ferulic acid in three batches of big Rhizoma Chuanxiong impulse pellets.
Fig. 2 is the release curve of gastrodine in three batches of big Rhizoma Chuanxiong impulse pellets.
Fig. 3 is gastrodine blood drug level figure.
The specific embodiment
A. carry the pill core prescription
The ball core:
Rhizoma Chuanxiong extract 48g
Rhizoma Gastrodiae extract 12g
MCC 28g
Lactose 10g
CCMCNa 2g
Water 60ml
B. sealing coat is write out a prescription: HPMC 2%
C. swell layer is write out a prescription: HPMC:Surelease (w/w 1:5) 60%
D. controlled release layer is write out a prescription: Surelease 5%
Technology:
The preparation of a ball core:
Rhizoma Gastrodiae, Rhizoma Chuanxiong extract (1:4) mixture and adjuvant are crossed 80 mesh sieves, and mixing adds suitable quantity of water and makes soft material, and (extruding frequency is 25～30Hz, and round as a ball frequency is 55Hz, preparation micropill of round as a ball times 6～7min) of micropill extruding under the round as a ball optimum condition.Take out micropill in 40 ℃ of oven dry 3～4h, the micropill between screening 18～24 orders carries out coating.
The b art for coating:
Get 18～24 order micropill 30g, adjusting fluidisation pressure is 0.4bar, atomizing pressure is 1.0bar, under 38～40 ℃, speed spray sealing coat coating solution HPMC with 0.5～1ml/min, coating finishes dry 20min, sprays swell layer Surelease/Hpmc (5:1) under the same conditions respectively, key-course coating solution Surelease.The weightening finish level of sealing coat is 2%, and the weightening finish level of expanding layer is 60%, and the weightening finish of the coating of controlled release layer is than being 5%.After coating finishes, in 50 ℃ of baking ovens, ripening 12h.
A. carry the pill core prescription
The ball core:
Rhizoma Chuanxiong extract 12g
Rhizoma Gastrodiae extract 3g
MCC 15g
Lactose 10g
CCMCNa 2g
Water 60ml
B. sealing coat is write out a prescription: HPMC 2%
C. swell layer is write out a prescription: HPMC:Surelease (w/w 1:5) 60%
D. controlled release layer is write out a prescription: Surelease 5%
Preparation technology:
The preparation of a ball core:
Rhizoma Gastrodiae, Rhizoma Chuanxiong extract (1:4) mixture and adjuvant are crossed 80 mesh sieves, and mixing adds suitable quantity of water and makes soft material, and (extruding frequency is 25～30Hz, and round as a ball frequency is 55Hz, preparation micropill of round as a ball times 6～7min) of micropill extruding under the round as a ball optimum condition.Take out micropill in 40 ℃ of oven dry 3～4h, the micropill between screening 18～24 orders carries out coating.
The b art for coating:
Get 18-24 order micropill 30g, adjusting fluidisation pressure is 0.4bar, atomizing pressure is 1.0bar, under 38～40 ℃, speed spray sealing coat coating solution HPMC with 0.5～1ml/min, coating finishes dry 20min, sprays swell layer Surelease/Hpmc (5:1) under the same conditions respectively, key-course coating solution Surelease.The weightening finish level of sealing coat is 2%, and the weightening finish level of expanding layer is 60%, and the weightening finish of the coating of controlled release layer is than being 5%.After coating finishes, in 50 ℃ of baking ovens, ripening 12h.
A. the medicine carrying particle cores is write out a prescription
Rhizoma Chuanxiong extract 48 g
Rhizoma Gastrodiae extract 12 g
MCC 24?g
Lactose 14g
CCMCNa 2g
B. sealing coat is write out a prescription: HPMC 2%
C. swell layer is write out a prescription: HPMC:Surelease (w/w 1:5) 60%
D. controlled release layer is write out a prescription: Surelease 5%
Technology:
The preparation of a ball core:
Rhizoma Gastrodiae, Rhizoma Chuanxiong extract (1:4) mixture and adjuvant are crossed 80 mesh sieves, and mixing adds suitable quantity of water and makes soft material, is equipped with granule with the extrusion granulator legal system.Take out granule in 40 ℃ of oven dry 3-4h, the granule between screening 18～24 orders carries out coating.
The b art for coating:
Get 16～24 order granule 30g, adjusting fluidisation pressure is 0.35 bar, atomizing pressure is 1.0bar, under 38～40 ℃, speed spray sealing coat coating solution HPMC with 0.5～1ml/min, coating finishes dry 20min, sprays swell layer Surelease/HPMC (5:1) under the same conditions respectively, key-course coating solution Surelease.The weightening finish level of sealing coat is 2%, and the weightening finish level of expanding layer is 60%, and the weightening finish of the coating of controlled release layer is than being 5%.After coating finishes, in 50 ℃ of baking ovens, ripening 12h.
A. the medicine carrying particle cores is write out a prescription
Rhizoma Chuanxiong extract 12g
Rhizoma Gastrodiae extract 3g
MCC 10g
Lactose 6g
CCMCNa 1g
B. sealing coat is write out a prescription: HPMC 2%
C. swell layer is write out a prescription: HPMC:Surelease (w/w 1:5) 60%
D. controlled release layer is write out a prescription: Surelease 5%
Technology:
The preparation of a ball core:
Rhizoma Gastrodiae, Rhizoma Chuanxiong extract (1:4) mixture and adjuvant are crossed 80 mesh sieves, and mixing adds suitable quantity of water and makes soft material, is equipped with granule with the extrusion granulator legal system.Take out granule in 40 ℃ of oven dry 3～4h, the granule between screening 18～24 orders carries out coating.
The b art for coating:
Get 18-24 order granule 30g, adjusting fluidisation pressure is 0.4bar, atomizing pressure is 1.0bar, under 38～40 ℃, speed spray sealing coat coating solution HPMC with 0.5～1ml/min, coating finishes dry 20min, sprays swell layer Surelease/Hpmc (5:1) under the same conditions respectively, key-course coating solution Surelease.The weightening finish level of sealing coat is 2%, and the weightening finish level of expanding layer is 60%, and the weightening finish of the coating of controlled release layer is than being 5%.After coating finishes, in 50 ℃ of baking ovens, ripening 12h.
Embodiment 5 tablets
A. the medicine carrying label is write out a prescription
Rhizoma Chuanxiong extract 48g
Rhizoma Gastrodiae extract 12g
MCC 27g
Lactose 28g
CCMCNa 20g
B. swell layer coating fluid prescription 0.05%～1% HPMC 4%
70% ethanol
C. block layer coating fluid prescription 5% EC 3%
PEG6000?3%
85% alcoholic solution
A. the medicine carrying label is write out a prescription
Rhizoma Chuanxiong extract 12g
Rhizoma Gastrodiae extract 3g
MCC 6g
Lactose 2g
CCMCNa 12g
B. swell layer coating fluid prescription 0.05%～1% HPMC 4%
70% ethanol
C. block layer coating fluid prescription 5%EC 3%
PEG6000?2%
85% alcoholic solution
Accurately take by weighing supplementary material by the inventory of writing out a prescription, cross 100 mesh sieves, fully mixing adds wetting agent system soft material, crosses the granulation of 24 mesh sieves, and 45 ℃ of dry 3h took out No. 2 sieves and No. 6 sieves, got the part that can cross No. 2 sieves and can not cross No. 6 sieves, tabletting.The control tablet hardness is at 7～9kg.25～35 plain sheets are put in the coating pan, and control coating pan rotating speed is 20～24rpm, and the external heat source temperature is regulated spray gun hydrojet size at 60～80 ℃, wraps swell layer and block layer respectively.Control swell layer and the weightening finish of block layer coating are 4% and 3%.Promptly.
Embodiment 7 microplates
A. the medicine carrying microplate sheet heart is write out a prescription
Rhizoma Chuanxiong extract 48g
Rhizoma Gastrodiae extract 12g
MCC 45.6g
Lactose 13.5g
CCMCNa 20.2g
B. swell layer coating fluid prescription 0.05%～1%HPMC 4%
70% ethanol
C. block layer coating fluid prescription 5%EC 3%
PEG6000?3%
85% alcoholic solution
A. the medicine carrying microplate sheet heart is write out a prescription
Rhizoma Chuanxiong extract 12g
Rhizoma Gastrodiae extract 3g
MCC 8.4g
Lactose 2.05g
CCMCNa 2.70g
B. swell layer coating fluid prescription 0.05%～1%HPMC 4%
70% ethanol
C. block layer coating fluid prescription 5%EC 3%
PEG6000?2%
85% alcoholic solution
Accurately take by weighing supplementary material by the inventory of writing out a prescription, cross 100 mesh sieves, fully mixing adds wetting agent system soft material, crosses the granulation of 24 mesh sieves, and 45 ℃ of dry 3h took out No. 2 sieves and No. 6 sieves, got the part that can cross No. 2 sieves and can not cross No. 6 sieves, tabletting.The control tablet hardness is at 7～9kg.35～45 plain sheets are put in the coating pan, and control coating pan rotating speed is 20～24rpm, and the external heat source temperature is regulated spray gun hydrojet size at 60～80 ℃, wraps swell layer and block layer respectively.Control swell layer and the weightening finish of block layer coating are 5% and 4%.Both.
Embodiment 9The release behaviour in vitro that contains the oral pulsed release system of Rhizoma Chuanxiong and Rhizoma Gastrodiae
External release evaluation: press three batches of pulse controlled release micro pills of example 1 preparation condition preparation, get a day dosing, under simulation human body gastrointestinal tract environment, carry out external stripping experiment, measure the drug release feature of each index components by release in vitro degree method respectively.
The result shows, as shown in Figure 1 and Figure 2, and basically identical between pulse controlled release micro pill time lag between different batches and rate of releasing drug, T
LagBe 5～6h, Tr is 3h, illustrates that this preparation technology's repeatability is better.
Embodiment 10The organism drug release feature that contains the oral pulsed release system of Rhizoma Chuanxiong and Rhizoma Gastrodiae
Adopt the SD rat to contain the interior pharmacokinetic studies of body of the oral pulsed release system of Rhizoma Chuanxiong and Rhizoma Gastrodiae, with Rhizoma Gastrodiae extract and Rhizoma Gastrodiae, Rhizoma Chuanxiong (4:1) mixed extract is reference, observation contains the oral pulsed release system of Rhizoma Chuanxiong and Rhizoma Gastrodiae at the intravital drug release feature of rat, after blood specimen collection and the processing, adopt the blood drug level of HPLC gastrodine, experimental result is as follows.
Table gastrodine blood drug level
* represent this time point not survey
The result shows, the pulse preparation is 268.0% with respect to the relative bioavailability of former formula extraction as shown in Figure 3, relative bioavailability with respect to Rhizoma Gastrodiae extract is 274.1%, illustrates that big Rhizoma Chuanxiong pulsatile drug delivery system compares with former formula extraction, has effectively improved drug bioavailability.
Claims (7)
1. a pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae is characterized in that said preparation is the multiple coatings preparation, and basic structure is respectively pastille core, swell layer, block layer composition from inside to outside.
2. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1 is characterized in that described pastille core is granule, micropill, micro chip and the tablet formulation form that contains medicine; Swell layer is the coatings of imbibition type adjuvant; Block layer contains coating adjuvants such as acrylic resin polymer or ethyl cellulose;
When a is micropill
Contain pill core and comprise Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, disintegrating agent, filler, by weight, its ratio is 3～12:12～48:1～10:69～60; Swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, and its weight ratio can be between 10:1～1:10, and the weightening finish of the coating of pastille core is 50%～80% relatively; Block layer contains hydrophobic coatings adjuvants such as acrylic resin polymer or ethyl cellulose, is 65%～100% with respect to the weightening finish of the coating of pastille core;
When b is microplate
The pastille core comprises Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, filler, disintegrating agent, its weight ratio is 4～11:29～39:37～49:7～21, wherein swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, swell layer and the weightening finish of block layer coating are than being controlled between 1:2～4:1, the swell layer weightening finish is for containing 3%～8% of the tablet heart, and the weightening finish of block layer swell layer is for containing 2%～6% of the tablet heart;
When c is tablet
The pastille core comprises Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, filler, disintegrating agent, its weight ratio is 4～11:29～39:29～42:19～38, wherein swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, swell layer and the weightening finish of block layer coating are than caning be controlled between 5:3～7:2, the swell layer weightening finish is for containing 3%～7% of the tablet heart, and the weightening finish of block layer swell layer is for containing 2%～5% of the tablet heart;
When d is granule
Contain pill core and comprise Rhizoma Gastrodiae effective site, Rhizoma Chuanxiong effective site, disintegrating agent, filler, by weight, its ratio is 16～40:4～10:1～10:68～38; Swell layer is by the pharmaceutic adjuvant with swelling behavior and having forming of hydrophobic performance, and its weight ratio can be between 10:1～1:10, and the weightening finish of the coating of pastille core is 50%～80% relatively; Block layer contains hydrophobic coatings adjuvants such as acrylic resin polymer or ethyl cellulose, is 65%～100% with respect to the weightening finish of the coating of pastille core.
3. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1 is characterized in that described disintegrating agent is selected from crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, the low mixture of getting a kind of in low hydroxypropyl cellulose, the microcrystalline Cellulose or some kinds.
4. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1 is characterized in that described swell layer coating material is hydroxypropyl methylcellulose, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, the low mixture of getting a kind of in low hydroxypropyl cellulose, the crospolyvinylpyrrolidone or some kinds.
5. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1 is characterized in that described block layer coating material is the mixture of a kind of of cellulose acetate-phthalate, Hydroxypropyl Methylcellulose Phathalate, phthalic acid polyvinyl alcohol ester, styrene maleic acid copolymerization, acrylic resin, Opadry enteric material, alginate jelly, Lac enteric-coating material, cellulose acetate, ethyl cellulose, polyacrylic resin class sustained release coating material or some kinds.
6. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1, the adjuvant that it is characterized in that described solubilising or raising medicine dispersion are the hydrophilic material that cyclodextrin, polyethylene glycols, polyvidone class, organic acid, saccharide and alcohols or other can be used for the solid dispersion preparation.
7. a kind of pulse release oral drug preparation that contains Rhizoma Chuanxiong and Rhizoma Gastrodiae according to claim 1 is characterized in that described filler is for selecting the pharmacy acceptable auxiliary for use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100693891A CN102133346A (en) | 2011-03-22 | 2011-03-22 | Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100693891A CN102133346A (en) | 2011-03-22 | 2011-03-22 | Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102133346A true CN102133346A (en) | 2011-07-27 |
Family
ID=44293359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100693891A Pending CN102133346A (en) | 2011-03-22 | 2011-03-22 | Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102133346A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301091A (en) * | 2012-03-12 | 2013-09-18 | 昆明制药集团股份有限公司 | Gastrodin double-pulse drug-release preparation |
| CN105796531A (en) * | 2016-04-13 | 2016-07-27 | 中国药科大学 | (R)-Lansoprazole time-selection pulse controlled-release pellet preparation and preparation method thereof |
| CN112316062A (en) * | 2020-11-17 | 2021-02-05 | 吉林大学中日联谊医院 | Traditional Chinese medicine composition for treating migraine, nasal gel, preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833647A (en) * | 2006-01-16 | 2006-09-20 | 北京正大绿洲医药科技有限公司 | Clinical preparation of compounded tall gastrodia tuber |
| CN1907313A (en) * | 2006-07-28 | 2007-02-07 | 中国人民解放军南京军区福州总医院 | Preparation method of Chinese traditional medicine slow release preparation for treating coronary heart disease and angina pectoris |
-
2011
- 2011-03-22 CN CN2011100693891A patent/CN102133346A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833647A (en) * | 2006-01-16 | 2006-09-20 | 北京正大绿洲医药科技有限公司 | Clinical preparation of compounded tall gastrodia tuber |
| CN1907313A (en) * | 2006-07-28 | 2007-02-07 | 中国人民解放军南京军区福州总医院 | Preparation method of Chinese traditional medicine slow release preparation for treating coronary heart disease and angina pectoris |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301091A (en) * | 2012-03-12 | 2013-09-18 | 昆明制药集团股份有限公司 | Gastrodin double-pulse drug-release preparation |
| CN103301091B (en) * | 2012-03-12 | 2014-12-03 | 昆明制药集团股份有限公司 | Gastrodin double-pulse drug-release preparation |
| CN105796531A (en) * | 2016-04-13 | 2016-07-27 | 中国药科大学 | (R)-Lansoprazole time-selection pulse controlled-release pellet preparation and preparation method thereof |
| CN112316062A (en) * | 2020-11-17 | 2021-02-05 | 吉林大学中日联谊医院 | Traditional Chinese medicine composition for treating migraine, nasal gel, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021129735A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
| CN101612195A (en) | A kind of polynary medicine-releasing system that contains Radix Salviae Miltiorrhizae and Radix Notoginseng | |
| EP3130334B1 (en) | Controlled-release solid preparation with partial coating | |
| CN102125531A (en) | Nifedipine sustained-release tablet | |
| CN102133346A (en) | Pulse releasing oral medicinal preparation containing ligusticum wallichii and rhizoma gastrodiae | |
| CN101606921B (en) | Acarbose solid sustained-release preparation and preparing method thereof | |
| CN101623280A (en) | Compound sustained release preparation for easing pain and preparation method thereof | |
| CN101502517A (en) | Glipizide enteric sustained-release preparation composition and method for preparing the same | |
| CN101480415B (en) | Cordyceps sinensis sustained and controlled release capsule and preparation method thereof | |
| CN101708169A (en) | Colonic targeting administration preparation containing active substance of paeonol and preparation method thereof | |
| CN102813662A (en) | New application of glycyrrhetinic acid-30-amined derivative | |
| CN101385733B (en) | Composite glycyrrhizin sustained release preparation | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation | |
| CN101756981B (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN103655585A (en) | Gastrodin controlled release preparation and preparation method thereof | |
| CN1985823A (en) | Slow released preparation containing metformin hydrochloride and rosiglitazone and its preparing process | |
| CN102526049A (en) | Compound diclofenac sodium slow-release preparation and preparation method thereof | |
| CN102836237A (en) | Integrally releasing Yang recuperating controlled and sustained release preparation and preparation method thereof | |
| CN102920662B (en) | Famciclovir sustained-release pellet, preparation method and application thereof | |
| CN102302780B (en) | Pharmaceutical composition for treating bronchial asthma | |
| CN104095867B (en) | Oral preparation for analgesia, and preparation method of oral preparation | |
| CN1506044A (en) | Slow-releasing prepn containing volatile oil and its prepn process | |
| CN101347439A (en) | Medicament for treating inflammatory bowel disease | |
| CN104940334A (en) | Hawthorn leaf extract solid dispersion sustained release capsule and preparation method thereof | |
| CN101869567A (en) | Medicament composition containing biguanide antidiabetic medicament and sartan antihypertensive medicament and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110727 |